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ABSTRACT The breadth and quality of scientific presentations on clinical and translational research into
respiratory infections at the 2015 European Respiratory Society (ERS) International Congress in
Amsterdam, the Netherlands, establishes this area as one of the leadings fields in pulmonology. The
host–pathogen relationship in chronic obstructive pulmonary disease, and the impact of comorbidities and
chronic treatment on clinical outcomes in patients with pneumonia were studied. Various communications
were dedicated to bronchiectasis and, in particular, to different prognostic and clinical aspects of this
disease, including chronic infection with Pseudomonas and inhaled antibiotic therapy. Recent data from the
World Health Organization showed that Europe has the highest number of multidrug-resistant tuberculosis
cases and the poorest countries have the least access to suitable treatments. Latent tuberculosis and different
screening programmes were also discussed with particular attention to risk factors such as HIV infection
and diabetes. Several biomarkers were proposed to distinguish between active tuberculosis and latent
infection. Major treatment trials were discussed (REMOX, RIFQUIN and STREAM). The possibility of
once-weekly treatment in the continuation phase (RIAQUIN) was especially exciting. The continuing rise
of Mycobacterium abscessus as a significant pathogen was noted. This article reviews some of the best
contributions from the Respiratory Infections Assembly to the 2015 ERS International Congress.
@ERSpublications
Members of @ERStalk Assembly 10 discuss the best presentations on respiratory infections at
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ADVANCES IN AMSTERDAM
RESPIRATORY INFECTIONS
Respiratory infections
A total of 197 abstracts for Group 10.1 of the Respiratory Infections Assembly (Assembly 10) and 171
abstracts for Group 10.2 (Tuberculosis) were presented at the 2015 European Respiratory Society (ERS)
International Congress. Communications were allocated into three oral presentation sessions, four poster
discussion sessions and six thematic poster sessions. Similarly to previous years, pneumonia has been one
of the leading topics, being the main subject of one oral session, one poster discussion and two thematic
poster sessions. Interestingly, several communications were also focused on bronchiectasis and infections
in other chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma.
The high number of communications on non-cystic fibrosis bronchiectasis characterised different sessions
during the congress, including one oral session, mostly dedicated to the analysis of risk factors
(i.e. comorbidities, Pseudomonas aeruginosa and thrombocytosis), one poster discussion and one thematic
poster session on different clinical and microbiological aspects of the disease. It is worth remarking on the
substantial increase in communications regarding bronchiectasis during the 2015 ERS International
Congress in comparison to previous congresses, indicating an increasing interest in this orphan disease.
Relevant public attraction was due to symposia, in particular those on the European Registry of Bronchiectasis,
the emergence of drug-resistant tuberculosis in Europe and on tuberculosis in the Russian Federation.
Pneumonia
Different studies of pneumonia were reported mainly focused on factors influencing the host–pathogen
interaction. Comorbidities and related medications seem to play a crucial role in determining clinical
outcomes of patients with community-acquired pneumonia (CAP). On one hand, a large (11844 cases),
retrospective, population-based study by GIL DE MIGUEL et al. [1] investigated different comorbidities associated
with an increased risk of pneumococcal pneumonia in order to provide evidence for the implementation
of pneumococcal prevention strategies. Patients with at least one comorbidity showed a higher mortality rate
(1.2 versus 0.5 per 1000 inhabitants, p<0.01), fatality rate (7.7% versus 5.7%, p<0.01), length of hospital stay
(9.6 versus 8.4 days, p<0.01) and costs (€4935 versus €4250, p<0.01) than patients without comorbidity. The
most relevant comorbidity increasing the risk of pneumococcal pneumonia across all age groups was
immunosuppression by accompanying hepatic, cardiovascular, renal or chronic respiratory disease.
However, a Greek multicentre study by MAKRODIMITRI et al. [2] showed that diabetes seems not to be
associated per se with greater mortality, although the clinical presentation was more severe due to an
increased rate of acute renal failure. The role of comorbidities is also potentially linked to chronic
medication, particularly in the elderly and in cases of recurrent pneumonia. In the last decade, inhaled
fluticasone and proton pump inhibitors were thought to increase the rate of pneumonia, while statins and
angiotensin-converting enzyme (ACE) inhibitors could play a preventive role, being associated with a
reduced mortality [3–13]. A Japanese study by ISHIFUJI et al. [14] on recurrent pneumonia in the elderly
showed that age >75 years (OR 2.60, 95% CI 1.06–6.43), previous pneumonia (OR 1.95, 95% CI
1.35–2.80), chronic pulmonary diseases (OR 1.86, 95% CI 1.24–2.78) and certain drugs, including
hypnotics (OR 2.06, 95% CI 1.28–3.31) and inhaled steroids (OR 1.78, 95% CI 1.12–2.84), increase the
risk of recurrent pneumonia, while ACE inhibitors seem to be protective (OR 0.22, 95% CI 0.05–0.91).
A multicentre study from the USA investigated the association between CAP and short- and long-term
risk of cardiovascular events and related mortality. During the last year, CORRALES-MEDINA and co-workers
[15, 16] described the increased risk of heart failure in the elderly population after pneumonia, although
the pathophysiological mechanisms are not completely clear. In line with these findings, SANZ et al. [17]
described tachyarrhythmia in one third of 2123 CAP patients and a clear association of pneumococcal
aetiology with poor outcomes (particularly with tachyarrhythmia). Further investigation is needed to
understand better the pathophysiology of this association in order to design future strategies to reduce the
cardiovascular mortality after CAP. A new animal (pig) model of pneumococcal infection was presented
by AMARO et al. [18], which was awarded as the “Best Abstract on Bacterial Pneumonia” prize. This model
potentially represents a great advance in the study of the pathophysiology of severe invasive pneumococcal
pneumonia, offering the possibility to assess the dynamics of systemic and local inflammation, host
response, and therapeutic efficacy of any novel treatment. In particular, the sequential measurements of
pulmonary mechanics, and sampling of respiratory and systemic biofluids and lung tissue will allow a
comprehensive assessment of the effects of pneumococcal infection on the lungs.
Respiratory infections in COPD
The ERS International Congress hosted presentations of various high-quality studies regarding the
host–pathogen balance in COPD-related infections. Microbiome analysis, and the correlation between its
compositions and different clinical outcomes was approached by different authors, providing a good example
of translational research getting closer to clinical practice. The longitudinal study by DICKER et al. [19] on
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exacerbations of COPD noted that the predominant species of microbiome were Streptococcus spp. or
Haemophilus spp., the latter being associated with a higher Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage. In addition, the authors observed that a higher GOLD stage was significantly associated
with reduced species diversity (p=0.009). In line with those findings, BRILL et al. [20] showed that Haemophilus
influenzae dominance could be associated with greater airway inflammation and bacterial burden. Moreover,
RODRIGO-TROYANO et al. [21] investigated exacerbations of COPD (ECOPD) due to P. aeruginosa in 401patients,
distinguishing between antibiotic-susceptible and -resistant strains (in vitro resistance to one or more class of
antibiotics). Interestingly, they observed that the isolation of a resistant P. aeruginosa was associated with a
reduced mortality risk for ECOPD, suggesting that the presence of a chronic airway infection/colonisation and
a possible adaptive immune response could modulate clinical outcomes.
Another interesting topic was the influence of inhaled corticosteroids on the susceptibility to viral
infections. STAPLES et al. [22] noted that the exposure to inhaled fluticasone might reduce the activation
and infection of T-cells and macrophages; these findings could explain less severe outcomes described in
patients receiving chronic inhaled steroids (COPD and asthma) during past influenza pandemics.
Conversely, XIA et al. [23] described, in an in vitro and in vivo study (mouse model), that infections
caused by respiratory syncytial virus and rhinovirus might induce insensitivity to glucocorticosteroids,
partially mediated by transforming growth factor (TGF)-β. This interesting study could explain the
pathophysiology of asthma/COPD exacerbations caused by viral infections as well as the potential
usefulness of TGF-modifying drugs for prevention/treatment.
Bronchiectasis
MCDONNELL et al. [24] investigated the role of comorbidity in clinical outcomes of bronchiectasis and found
that there was a significant association between the number of comorbidities and the Bronchiectasis Severity
Index (BSI) (low, 2.9; intermediate, 3.8; high, 4.3) [25] (p<0.0001). Comorbidities associated with mortality
included COPD (OR 3.95, p<0.0001), connective tissue disease (OR 3.37, p<0.0001), tumours (OR 4.45,
p<0.0001), metastatic cancers (OR 10.4, p<0.0001), pulmonary hypertension (OR 3.62, p=0.04) and iron
deficiency-related anaemia (OR 4.85, p=0.005). SALEH et al. reported interesting data on cardiovascular
comorbidity in patients with bronchiectasis [26]. The analysis of aortic stiffness (pulse-wave velocity), and
cardiac and inflammatory biomarkers among 101 patients with stable bronchiectasis seem to confirm the high
cardiovascular risk in these patients. This risk was associated with both exacerbations and an impaired lung
function. RENTON et al. [27] found that thrombocytosis, a marker of both inflammation and cardiovascular
disease, was associated with an increased severity of bronchiectasis, exacerbation frequency, mortality and
reduced quality of life.
Numerous communications were also dedicated to nontuberculous mycobacterial (NTM) infections in
bronchiectasis. Notable aspects were the breadth of geographical coverage, with researchers from Japan,
the UK and India all contributing. Both basic science studies and clinical trials were focused on
biomarkers and antibiotics to treat refractory NTM. The prevalence of NTM infections across different
areas of the world was a subject of active debate. The symposium on the European registry of
bronchiectasis (EMBARC) [28] was one of the most crowded sessions of the Congress, with almost 2000
attendees. An interesting overview was provided by ALIBERTI et al. [29] on the heterogeneity of the disease
(clinical presentation, aetiology and research activity) and on two other crucial aspects of the clinical
management of the disease: antibiotic therapy (oral and inhaled) and physiotherapy. Finally, preliminary
data from almost 1300 patients recruited to the EMBARC registry focused the attention on disease
severity, current treatments (particularly for P. aeruginosa) across Europe, the impact of comorbidities
(including COPD) and future expectations for the registry.
During the Congress, research priorities in bronchiectasis previously identified through a Delphi process
by patients and experts of the EMBARC Roadmap Working Group were shared and discussed during an
oral presentation by ALIBERTI et al. [30]. Among the 55 research priorities, the following received special
attention. 1) What are the causes of bronchiectasis? 2) What are the triggers of an exacerbation? 3) When
should airway drainage techniques be started in patients with bronchiectasis, and which is the most
effective and pragmatic? 4) What are the risk factors and causes of fast progression and poor outcomes in
patients with bronchiectasis?
Immunosuppression and severe pneumonia
Various communications were dedicated to fungal infection and, in particular, to pulmonary aspergillosis in
immunocompromised patients. Interesting data were presented by SUGISAKI et al. [31] on chronic pulmonary
aspergillosis (CPA). The authors showed how underlying respiratory disease influences the clinical features
and prognosis of patients with CPA. For instance, patients with emphysema and/or interstitial lung diseases
show more rapid progression of CPA, demonstrated by a higher rate of antigen positivity and lower antibody
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titres. LIN et al. [32] analysed a series of 22 cases of CPA over a 5-year period, reporting a higher COPD
prevalence (36.4%) than in previous studies, and suggested a predisposing role for fungal infections even in
the absence of immunosuppressive therapy. In order to improve clinical management of CPA and to reduce
diagnostic delay, ROZALIYANI et al. [33] proposed a diagnostic score based on four variables: value of lung
excreted galactomannan, solid-organ malignancy, pulmonary tuberculosis and systemic corticosteroids. This
model will require further validation but it could represent a promising tool to reduce infection-related
mortality similarly to severity scores used in other respiratory infections, such as the Pneumonia Severity
Index, according to FINE et al. [34] and LUNA et al. [35].
A retrospective, matched case–control study by DESSEIGNE et al. [36] investigated Pneumocystis jirovecii
pneumonia (PCP) in immunosuppressed patients with solid tumours. They found that severe
lymphopenia, >1 month corticosteroid treatment and thoracic radiotherapy were significant risk factors for
the development of PCP.
Translational research in respiratory infections
A significant number of research projects were presented this year at the Congress, filling a poster discussion
session and various thematic poster sessions. Several aspects of the immunological and inflammatory host
response to different pathogens were presented. Various communications focused on the host response to
bacterial (e.g. H. influenzae, P. aeruginosa and Streptococcus pneumoniae) and viral (e.g. H1N1 influenza
virus, respiratory syncytial virus and rhinovirus) infections in healthy subjects and in patients with chronic
respiratory diseases, such as asthma. These new findings will hopefully contribute to a better understanding
of the host–pathogen interaction and identify novel beneficial approaches beyond antibiotic therapy.
Tuberculosis
Multidrug-resistant tuberculosis
The symposium “The emergence of drug-resistant tuberculosis in Europe: no cure possible” began with a
patient’s perspective following successful treatment for multidrug-resistant tuberculosis (MDR-TB) in Romania.
Most notable were the adverse events, the duration of treatment, the experience of relapse, and the stigma
afforded to the patient by her relatives and social contacts. Dick van Soolingen (Nijmegen, the Netherlands)
championed his contention that the Beijing clade is more virulent than other clades of the Mycobacterium
tuberculosis complex by referring to a cluster of 470 individuals (384 from Estonia) who had been infected with
this multidrug resistance strain [37]. He suggested from the work of COMAS et al. [38] that compensatory
changes for the rpoB mutations in other ribosomal polymerases returned protein manufacture to near normal
levels. Furthermore, four proteins that distinguish modern from ancient Beijing strains were shown to be
Mmp14 (Rv450c), Rv1269c, CobC (Rv2231c) and SseA (Rv3283), together with three efflux pumps, which
might affect intrabacillary levels of antibiotics [39]. A lively discussion noted the potential for founder effects,
selection bias (only culture-positive samples can be sequenced) and the role of social group characteristics in
the spread of this strain. Unpublished data showed that rifampicin per se induced DosR-regulated genes.
Marieke J. van der Werf (European Centre for Disease Prevention and Control, Stockholm, Sweden)
discussed the epidemiology of MDR-TB within the European Union, noting that Romania accounted for
25% of all MDR-TB but had the lowest rate of routine drug sensitivity testing (DST). In contrast,
Christoph Lange (Borstel, Germany) used data from the World Health Organization (WHO) European
Region to show that Europe accounted for the highest number of cases of and continued increase in
MDR-TB of all the WHO regions. The relative costs of treatment depending on drug resistance patterns
showed that the poorest countries of Europe and those with the most significant MDR-TB problem had
more limited access to suitable drugs and were paying proportionally more for each second-line drug [40].
The mean costs for even the most expensive drugs that can cure drug-resistant tuberculosis compare
favourably with chemotherapy for lung cancer and 10 years’ palliative treatment for COPD or asthma
according to RUTTEN-VAN MÖLKEN et al. [41] and BRIGGS et al. [42]. The suggestion was made that in those
with fluoroquinolone-resistant tuberculosis, as in extensively drug-resistant tuberculosis (XDR-TB) or
pre-XDR-TB, that bedaquiline should be used as the replacement drug of choice.
A symposium on tuberculosis in the Russian Federation noted the problems in containing drug resistance.
Results of the implementation of routine DST in three oblasts noted a high rate of MDR-TB [43]. Delays
in DST were important in the extended use of first-line drugs and, although MDR-TB treatment failure
was only significant if the delay was >24 months, the cost of further transmission to the community was
thought to be high, as proved by BATYRSHINA [45].
Latent tuberculosis infection and screening
In a Hot Topics session, Giovanni Sotgiu gave an overview of latent tuberculosis infection (LTBI). A
survey of national guidelines against the WHO standard for screening for LTBI indicated most compliance
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when screening contacts and before anti-tumour necrosis factor (TNF) use, but poorer compliance for
HIV-infected patients, patients on dialysis or undergoing transplantation, and those with silicosis. The UK
programme for screening new entrants was presented. ERKENS et al. [45] noted that preventive treatment
with 4 months rifampicin had a higher completion rate in the Netherlands than standard 6–9 months
isoniazid. Two large studies from South Korea were presented: KIM et al. [46] showed that even in those
with a positive QuantiFERON Gold In-Tube test (Qiagen, Hilden, Germany), if the tuberculin (purified
protein derivative (PPD)) skin test diameter was <10 mm, tuberculosis did not develop (0 out of 152 PPD+
contacts out of 3088 tested in total); another study by KIM et al. [47] on screening for diabetes mellitus in
4.9 million subjects identified 11699 with tuberculosis but the association showed a stronger link with age
as a confounder for both diabetes and tuberculosis. Surprisingly, JENSEN et al. [48] showed that sputum
screening in high-risk groups in Copenhagen, Denmark, identified 40 cases of tuberculosis, which were
then compared to 56 patients detected by passive screening and shown to have fewer smear-negative
samples. This contrasted with the UK experience of MIDDLETON et al. [49] in 1039 asylum seekers where
333 out of 379 were referred to a tuberculosis clinic with symptoms or a history of tuberculosis contact, of
whom just over 10% required preventive treatment and a further 15 were given a bacille Calmette–Guérin
vaccination. In Portugal, according to SOUSA et al. [50], a fall in HIV infection was associated with a
concurrent fall in tuberculosis, whereas a rise in unemployment was associated with a small increase in
tuberculosis. Data from OZGULER et al. [51] on when to restart TNF treatment if tuberculosis developed
were incomplete as a new infection was the cause of tuberculosis as confirmed by a difference in strain
typing. Another case of tuberculosis developing during TNF treatment for inflammatory bowel disease
again suggested that a new infection rather than reactivation was responsible.
Tuberculosis biomarkers
GARCÍA et al. [52] reported the mycobactericidal whole-blood activity in genetically related tuberculosis
contacts. In the past, this test has been used to monitor clinical outcome of tuberculosis patients as discussed
by WALLIS and co-workers [53, 54]. This study used whole blood mycobactericidal activity to evaluate
tuberculosis susceptibility in family contacts and found lower antimycobacterial activity than in the general
population, suggesting a genetic susceptibility to tuberculosis, although other immunological explanations are
possible. LOSI et al. [55] reported on the additional benefits of M. tuberculosis-specific antigens to improve
upon the interferon (IFN)-γ release assays. New antigens were identified by this approach to distinguish
LTBI from active disease [56–58]. They screened in silico for human leukocyte antigen DR epitopes of
M. tuberculosis proteins in 44 clinical strain genomes. Proteins were ranked accordingly to produce an
immunogenetic model of tuberculosis susceptibility. Proteins containing T- and B-cell epitopes were selected,
and B-cell epitopes produced as mimotope peptides. Among 121 relevant protein orthologues, 22 proteins
were M. tuberculosis-specific and were used to prepare 167 mimotopes. 116 of these mimotopes presented a
significantly higher IFN-γ response in those with active tuberculosis. Antibody testing of the mimotopes gave
sensitivities ranging from 27 to 100% (average 66%) with a specificity of 100%. These are promising tools to
distinguish latent from active tuberculosis, and to explore at both the diagnostic and pathogenetic levels.
PETRUCCIOLI et al. [59] reported the evaluation of the accuracy of several immune experimental diagnostic
tools to distinguish active tuberculosis from latent infection. They combined several experimental
immunological approaches based on the detection of IFN-γ/TNF-α bifunctional CD4+ T cells [60], on
central memory phenotypes of IFN-γ-specific CD4+ T-cells [61] and an assay based on the “CD27 ratio”
[62], discussed in detail in another presentation [63]. By logistic regression followed by receiver operating
characteristic analysis, the best combination to discriminate active tuberculosis from LTBI was generated
by the use of the detection of the central memory CD4+ T-cells and the CD27 ratio (area under the curve
0.96, 95% CI 0.87–0.99; p<0.0001). If confirmed in larger numbers, this approach may help to distinguish
tuberculosis disease from LTBI.
WOLF et al. [64] reported on a novel biomarker that was more strongly associated with tuberculosis treatment
outcome than conventional or genotypic methods. They developed a modified mycobacteriophage with a
fluorescent reporter (F2GFP10), which is able to detect metabolically active M. tuberculosis in biological
samples such as sputum. They compared the F2GFP10 assay enumerated by flow cytometry to conventional
M. tuberculosis culture and GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) in serial sputum samples
from 20 patients with active tuberculosis who were on treatment. The 6-month treatment outcome was
defined by standard WHO criteria and suggested that the new test might have greater accuracy in predicting
the outcome of treatment.
Short-course chemotherapy for active tuberculosis
In a Year in Review session, Stephen H. Gillespie (St Andrew’s, UK) presented on the REMOX trial [65].
He noted the superior early bactericidal activity and 2-month culture conversion rates in patients treated
with moxifloxacin compared to the standard regimen. However, despite this early effectiveness, the
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standard 6-month regimen could not be shortened to 4 months. PHILLIPS et al. [66] considered that the
3-month culture conversion rate might be a better predictor of outcome than that at 2 months, although
in the REMOX trial relapse occurred in those who had a negative sputum culture. Gillespie suggested that
one possibility for the ineffectiveness of 4-month regimens was the initial dose of rifampicin [67].
Alternatively, moxifloxacin might have created more persisters, slowly metabolising and using stored lipids
as a substrate [68]. Amina Jindani (London, UK) then reviewed other 4-month regimens, noting the high
variability of relapse rates ranging from 11% with 2SHRZ/2HRZ to 40% with 2SHRZ/2H [69]. The
RIFAQUIN trial showed similar rates of relapse (17%) for a 4-month regimen but notably, the 6-month
regimen with weekly rifapentin and isoniazid in the continuation phase was as effective as the standard
regimen [69]. Christian Lienhardt (Marseille, France) then reiterated these findings, noting the loss of
gatifloxacin from the pharmacopoeia due to adverse effects with a brief overview of the OFLOTUB trial [70].
Sarah Meredith (London) gave an update of the current STREAM trials and the reassessment of variants of
the Bangladesh regimen in randomised controlled trials [71]. Shorter treatments for drug-sensitive and
-resistant tuberculosis against the standard regimens will probably require a better understanding of the
persister stage of M. tuberculosis.
Patients with late sputum conversion were described but no poster confirmed adequate treatment
adherence in the initial phase of treatment. A poster by BAE et al. [72] showed that those without sputum
conversion at 4 months had a history of previous tuberculosis, acquired multidrug resistance having
initially been rifampicin sensitive and had just under 70% treatment success. MEJRI et al. [73] showed a
link between diagnostic delays and retrospective assessment of pulmonary cavitation. The importance of
early second-line drug sensitivity testing for those with rifampicin resistance was emphasised by UTSAV
et al. [74]. Systematic management of drug resistance was important in achieving good outcomes [75, 76].
The toxicity of linezolid was confirmed, with almost 80% experiencing adverse effects [77] and a fifth
developed peripheral neuropathy, half of which was irreversible [78]. Nonadherence to treatment for
MDR-TB regimens was frequently due to adverse events (81%) [79]. A high rate of pre-XDR-TB due to
fluoroquinolone resistance was noted in Karachi, Pakistan (363 out of 919 patients with MDR-TB) [80],
and Kiev, Ukraine [81]. Rates of cure of XDR-TB continue to be similar to those reported with no
treatment in the pre-antibiotic era [81]. There were several presentations noting the outpatient
management of M/XDR-TB, although all were evaluated in terms of patient treatment outcomes, which
were not different [82], rather than transmission of disease. Importantly, nosocomial transmission of
MDR-TB occurred in 75% of 173 patients who developed MDR-TB having been admitted as inpatients
with a fully sensitive strain. The conclusion remains that an early finding of rifampicin resistance should
be followed up by rapid second-line testing, preferably genotypically, in order to tailor the drug regimen
appropriately, and that systems must be in place to ensure adequate infection control.
Treatment regimens and monitoring
Moxifloxacin is often used to replace isoniazid in treatment regimens and is effective [83]. Some in the
audience raised concerns about the development of resistance to fluoroquinolones in potential
pre-MDR-TB/XDR-TB and recommended standard regimens using streptomycin or a longer course with
REZ. In vitro evidence was presented that mefloquine, in doses currently used for malarial prevention, can
kill M. tuberculosis [84]; other possible drugs were the phenothiazines [85] and others, which in in vitro
studies showed a significant percentage of strains with a minimum inhibitory concentration (MIC)
apparently above the maximal permissible drug concentrations, although with some technical problems in
determining the MIC [86]. A cohort study by NIKOLAYAN et al. [87] was used to justify the use of linezolid,
bedaquiline and imipenem as treatment for XDR-TB (Armenia/Russia).
New methods of treatment monitoring were discussed. A study by CORONEL et al. [88] using AERONOSE
suggested there might be changes in exhaled breath in the first 2 months of treatment. The use of
magnetic resonance imaging for spinal tuberculosis was advocated by MCGHEE et al. [89] but the audience
agreed that distinguishing bacterial cure from continuing inflammatory responses and bone remodelling
made the use of such an expensive test impractical, especially in the absence of evidence from a
randomised controlled trial. Whether there might be strain-related problems with treatment success and
relapse was considered by HANG et al. [90] but discounted in the absence of clinical data regarding
adherence and other patient-related variables. Video directly observed therapy (vDOT) via mobile phones
was the subject of a preliminary trial described by FALZON et al. [91] but participants felt that adherence
with vDOT was as likely as without and the intervention could not be used in those in whom adherence
was a problem, but rather in national programmes where universal directly observed therapy was required.
Nontuberculous mycobacteria
Suggestions that NTM and tuberculosis could be radiographically distinguished were made by CHU et al. [92].
The serodiagnosis of Mycobacterium avium complex was again promoted by the Japanese progenitors
ERJ Open Res 2016; 2: 00049-2016 | DOI: 10.1183/23120541.00049-2016 6
RESPIRATORY INFECTIONS | E. POLVERINO ET AL.
of the glycopeptidolipid antigen test [93, 94]. A poster by LEE et al. [95] suggested that CA 19-9 might be
a useful marker of treatment response for M. abscessus pulmonary disease. Laboratory isolation of NTMs
due to water contamination are common, according to D’ANTONIO et al. [96]. The distinction between
isolation and NTM disease remains important, especially in the context of HIV co-infection, as pointed
out by BHAT et al. [97].
Perspectives for 2016 and beyond
A better understanding of host-related risk factors influencing clinical outcomes in CAP is expected in the
future, and could lead to the development of preventive and therapeutic strategies in specific subsets of the
population. The identification of different clinical phenotypes and specific prognostic factors is also
expected for patients with bronchiectasis due to the increasing number of publications on the field.
Moreover, new inhaled antibiotics are expected to be introduced for treatment of bronchiectasis and NTM
in the future, subject to confirmatory randomised controlled trials. Finally, the growing research on
microbiomes in chronic respiratory diseases such as COPD and bronchiectasis will potentially identify
specific disease patterns (stable and exacerbations, chronic infection, etc.) and clinical applications of this
innovative and interesting microbiological technique.
The 2015 ERS International Congress in Amsterdam highlighted new approaches in immunodiagnostics and
biomarkers for tuberculosis with some potential tests, which now need to be evaluated in larger clinical
samples. Emerging MDR-TB/XDR-TB remains a major concern of clinicians throughout the European
region, and basic DST and genetic tests need to be more readily available to contain this problem. The
4-month trials have highlighted the differences between the actively dividing population treated in the initial
intensive phase of tuberculosis treatment and the more slowly dividing populations that are treated in the
continuation phase. This is an area ripe for basic research to contribute real clinical advances. We are looking
forward to the next ERS International Congress in London in 2016, where such topics will be addressed.
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